IL1B and COVID-19: Clinical data indicate that a hyperinflammatory response (an excessive release of pro-inflammatory cytokines e.g. interleukin 6 (IL-6) and IL-1b with secondary tissue damage) to SARS-CoV-2, contributes to disease severity and death in patients affected by COVID-19 [9].